Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Lenti-D (elivaldogene autotemcel) in Pediatric Cerebral Adrenoleukodystrophy
2018-001145-14Phase 3Unknown
- Sponsor
- bluebird bio, Inc.
- Start
- Oct 2018
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elivaldogene autotemcel in cerebral adrenoleukodystrophy (CALD) and adrenoleukodystrophy (ALD), sponsored by bluebird bio, Inc. Status: unknown.
02
Drugs
elivaldogene autotemcel
03
Conditions
cerebral adrenoleukodystrophy (CALD)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on 2018-001145-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001145-14.